Randall Lane
Physician Assistant · Marshall, TXNPI 1558343681
Payments from drug & device makers
Across 372 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$725
- Lilly USA, LLC$689
- AstraZeneca$635
- AbbVie$586
- Amgen$485
- Pfizer$377
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,63498%
- Education$1252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $725 |
| Lilly USA, LLC | 51 | $689 |
| AstraZeneca | 35 | $635 |
| AbbVie | 41 | $586 |
| Amgen(2 entities) | 34 | $485 |
| Pfizer | 26 | $377 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $343 |
| Novartis | 14 | $229 |
| Boehringer Ingelheim | 13 | $223 |
| Bayer | 8 | $184 |
| Merck | 13 | $180 |
| Kowa Pharmaceuticals America, Inc. | 8 | $119 |
| GSK | 6 | $117 |
| Antares Pharma, Inc. | 6 | $111 |
| Astellas Pharma US Inc | 1 | $100 |
| Idorsia Pharmaceuticals US Inc | 5 | $98 |
| Exact Sciences | 3 | $51 |
| Shield Therapeutics Inc | 3 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Dynavax Technologies Corporation | 2 | $41 |
| Almatica Pharma LLC | 2 | $38 |
| Currax Pharmaceuticals LLC | 2 | $38 |
| Clarus Therapeutics Inc. | 3 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 3 | $35 |
| Eisai Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Axsome Therapeutics, Inc. | 1 | $9 |
How this compares
$5,759 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 67 | $68,922 |
| OzempicSemaglutide | 49 | $66,785 |
| MounjaroTirzepatide | 19 | $25,983 |
| XareltoRivaroxaban | 23 | $13,416 |
| Repatha SureclickEvolocumab | 16 | $13,151 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $12,717 |
| Rosuvastatin Calcium | 258 | $2,898 |
| Levothyroxine Sodium | 225 | $2,663 |
| Gabapentin | 93 | $1,255 |
| Pantoprazole Sodium | 105 | $1,176 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 54 | $1,010 |
| Atorvastatin Calcium | 139 | $953 |
| Pioglitazone Hcl | 69 | $948 |
| Oxybutynin Chloride ErOxybutynin Chloride | 25 | $874 |
| Metformin Hcl | 92 | $791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $635 | $68,92267 claims |
| Novo NordiskOzempic | $725 | $66,78549 claims |
| Lilly USA, LLCMounjaro | $689 | $25,98319 claims |
| Johnson & JohnsonXarelto | $15 | $13,41623 claims |
| MerckJanumet | $180 | $12,71711 claims |
| AbbVieSynthroid | $586 | $53812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Marshall
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.